IRRAS announces outcome of the fully guaranteed rights issue of 217 million SEK.
“During these unprecedented SARS-CoV-2 times across the globe, IRRAS’ focus remains on the patients and physicians who need our support and access to our neurocritical care products,” said Kleanthis G. Xanthopoulos, President & CEO of IRRAS. “This round of financing and outcome of the rights issue, which was completed in very difficult market conditions, enables IRRAS to focus and expand our commercial capabilities and deliver our innovative IRRAflow and Hummingbird technologies to additional markets and distribution partners around the world.”
Through the rights issue, IRRAS’ share capital will increase with SEK 1,123,901 to SEK 1,988,440 and the total number of shares will increase with 37,463,366 shares. The number of shares in IRRAS after the rights issue will amount to 66,281,340 shares.
The new shares are expected to be listed for trading on Nasdaq First North Premier Growth Market around 22 April 2020.
Photo of Kleanthis Xanthopoulos, CEO, IRRAS